[Secondary effects of adjuvant therapy].
Giai
M
M
De Fabiani
E
E
Lamberto
A
A
Cortese
P
P
Giardina
G
G
D000505:Alopecia / Q000139:chemically induced; D000568:Amenorrhea / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000009:adverse effects; D003556:Cystitis / Q000139:chemically induced; D004317:Doxorubicin / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D006321:Heart / Q000187:drug effects; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects; D008936:Mitolactol / Q000009:adverse effects; D008937:Mitomycins / Q000009:adverse effects; D009369:Neoplasms / Q000139:chemically induced
D008937:Mitomycins; D004317:Doxorubicin; D003520:Cyclophosphamide; D008936:Mitolactol; D005472:Fluorouracil; D008727:Methotrexate
Effetti secondari delle terapie adiuvanti.